Your browser doesn't support javascript.
loading
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
Kalunian, Kenneth C; Furie, Richard; Morand, Eric F; Bruce, Ian N; Manzi, Susan; Tanaka, Yoshiya; Winthrop, Kevin; Hupka, Ihor; Zhang, Lijin Jinny; Werther, Shanti; Abreu, Gabriel; Hultquist, Micki; Tummala, Raj; Lindholm, Catharina; Al-Mossawi, Hussein.
Afiliação
  • Kalunian KC; Division of Rheumatology, Allergy and Immunology, University of California San Diego School of Medicine, La Jolla, California.
  • Furie R; Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York.
  • Morand EF; School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.
  • Bruce IN; Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, and Manchester Academic Health Science Centre, Manchester, UK.
  • Manzi S; Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, Pennsylvania.
  • Tanaka Y; The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
  • Winthrop K; School of Public Health at Oregon Health and Science University, Portland, Oregon.
  • Hupka I; Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland.
  • Zhang LJ; Global Patient Safety, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
  • Werther S; Global Patient Safety, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Abreu G; Biometrics, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Hultquist M; Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
  • Tummala R; Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
  • Lindholm C; Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Al-Mossawi H; Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Arthritis Rheumatol ; 75(2): 253-265, 2023 02.
Article em En | MEDLINE | ID: mdl-36369793
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Lúpus Eritematoso Sistêmico Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Lúpus Eritematoso Sistêmico Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article